NCT00008554Unknown3 期
A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults
Glaxo Wellcome23 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2000年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 210
- 试验地点
- 23
研究概览
简要总结
The purpose of this study is to compare GW433908 and nelfinavir when each is given with abacavir and lamivudine to HIV patients who have not taken antiretroviral drugs.
详细描述
Patients are randomized in a 2:1 scheme to 1 of 2 treatment groups. Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC. Patients undergo safety and efficacy assessments at the Screening Visit, Day 1 (Entry), and Weeks 1, 2, 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter. A follow-up visit is performed 4 weeks after the permanent discontinuation of study drug. Detailed assessments for the development of lipodystrophy/fat redistribution occur at Day 1, Week 24, Week 48, and every 16 weeks thereafter. Patients have examinations and laboratory tests performed at visits.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are at least 13 years old (consent of parent or guardian required if under 18).
- •Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children.
- •Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRT) or protease inhibitor (PI).
- •Have a viral load (amount of HIV in the blood) of 5,000 copies/ml or more, or have a positive result at the screening visit.
排除标准
- •Patients will not be eligible for this study if they:
- •Abuse drugs or alcohol in a way that would interfere with the study, in the opinion of the doctor. Patients stable on methadone will be considered for participation.
- •Have an active/acute CDC Category C event.
- •Are unable to absorb or take medicines by mouth.
- •Are pregnant or breast-feeding.
- •Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient.
- •Have had pancreatitis or hepatitis within the last 6 months.
- •Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study.
- •Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken.
- •Have received HIV vaccine within 3 months before the study drug will be taken.
- •Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study.
- •Have received experimental treatments.
- •Have allergies which might interfere with the study, in the opinion of the doctor.
研究者
研究点 (23)
Loading locations...
相似试验
终止
3 期
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorHIV InfectionsNCT00028067Bristol-Myers Squibb500
进行中（未招募）
不适用
Comparative Study of Entecavir vs Adefovir vs the Combination in Lamivudine- Refractory Chronic Hepatitis B Subjects The DEFINE Study Revised Protocol 01 - The DEFINE StudyCHRONIC HEPATITIS B VIRUSMedDRA version: 9.1Level: LLTClassification code 10019731Term: Hepatitis BEUCTR2006-000422-31-ITBristol-Myers Squibb International Corporation462
已完成
不适用
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsChronic Hepatitis CNCT00854802Debiopharm International SA290
进行中（未招募）
不适用
A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs CombinationEntecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: TheDEFINE StudyRevised Protocol 02, incorporating protocol amendment 02 (Version 2.0, date 23-Jan-2007), protocol amendment 03 (Version 4.0, date 07-Nov-2007) and Administrative Letter 01. - The DEFINE StudyCHRONIC HEPATITIS B VIRUSMedDRA version: 9.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-000422-31-GRBristol-Myers Squibb International Corporation462
招募中
不适用
In-vivo Bioequivalence Test of Favipiravir® tablet with brand drugs (AVIGAN® 200mgTAYOMA Chemical Ind. Co)..IRCT20200105046010N30ABIDI Pharmaceutical Company24